In patients with HF-pEF, obesity, and no diabetes, semaglutide causes weight loss, symptom improvement, and fewer cardiac events (STEP-HFpEF)

Clinical Question

In adults with heart failure with preserved ejection fraction and obesity but no diabetes, does semaglutide provide symptomatic benefit and weight loss? 

Bottom line

In this fairly narrow group of adults with HFpEF, obesity, moderate symptoms, and no diabetes, semaglutide resulted in symptomatic improvement, weight loss, and fewer cardiac events. Another trial is underway that includes similar patients who have diabetes. 1b

Study design: Randomized controlled trial (double-blinded)

Funding: Industry

Setting: Outpatient (any)

Reviewer

Mark H. Ebell, MD, MS
Professor
University of Georgia
Athens, GA


Discuss this POEM


Comments

Arup Kumar Dhara

Impact assessment

Excellent

Anonymous

HT-PEE.OBESITYAND NONDIABETES . SEMAGLUTIDECAUSESWEIGHTLOSS

GOOD TO KNOW